Quantcast

Latest Targeted therapy Stories

2014-03-05 10:44:37

By eliminating Mcl-1, radiation and chemotherapies could be more effective in treating the most common and deadly of all cancers Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments. Non-small cell lung cancer (NSCLC) makes up about 85 percent of the nearly 160,000 Americans expected to die this year from lung cancer, which by far...

2014-03-04 12:25:51

SAN DIEGO and OSAKA, Japan, March 4, 2014 /PRNewswire/ -- TRACON Pharmaceuticals (TRACON) and Santen Pharmaceutical Co., Ltd. (Santen) announced today that they have entered into an exclusive agreement for the development and global commercialization of TRACON's anti-endoglin antibodies, including TRC105, in ophthalmology. Pre-clinical and clinical data from TRACON's ongoing development of TRC105 in combination with anti-VEGF products in oncology indicate inhibiting both the...

2014-03-03 15:25:51

Researchers from UCLA's Jonsson Comprehensive Cancer Center have developed an innovative cancer-fighting technique in which custom-designed nanoparticles carry chemotherapy drugs directly to tumor cells and release their cargo when triggered by a two-photon laser in the infrared red wavelength. The research findings by UCLA's Jeffrey Zink, a professor of chemistry and biochemistry, and Fuyu Tamanoi, a professor of microbiology, immunology and molecular genetics, and their colleagues were...

2014-02-21 08:26:00

DALLAS, February 21, 2014 /PRNewswire/ -- RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as monoclonal antibodies market forecasts in breast cancer, colorectal cancer as well as gastric and esophageal cancers to 2019. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and...

2014-02-20 23:24:59

The global market for antibody drug conjugates was valued at $179 million in 2012 and is estimated at $396 million for 2013. BCC Research projects the market to grow to nearly $2.8 billion by 2018, and register a five-year compound annual growth rate of 48.1% from 2013 to 2018. Wellesley, MA (PRWEB) February 20, 2014 According to a new technical market research report Antibody Drug Conjugates: Technologies and Global Markets, from BCC Research (http://www.bccresearch.com), the global...

2014-02-18 23:30:30

Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) February 18, 2014 Andarix Pharmaceuticals, a clinical stage company, announces that it has been selected to present its targeted lung cancer therapy at the 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting, also known as the Santa Monica Lung Cancer Meeting. This annual invitation-only meeting gathers the top scientists and clinicians to discuss the latest...

2014-02-14 23:02:22

New research report “Breast Cancer: New targeted therapies transform treatment - KOL Insight” worked out by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB) February 14, 2014 Currently, hormone, immuno-, chemo- and target therapies are the four main types of cancer therapy, with target therapy sector accounting for the dominant share of the overall cancer therapy market. In spite of the continuous improvements in the cancer diagnosis together with the development...

2014-02-13 04:20:48

Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES, France and BANGALORE, India, February 13, 2014 /PRNewswire/ -- Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and...

2014-02-12 23:25:02

ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United States, today announced the selection of Foundation Medicine as its preferred partner for comprehensive cancer genomic profiling services. Frisco, Texas (PRWEB) February 12, 2014 ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related